319460-94-1 AG13958 AKSci SYN1004
 
 
Loading Please Wait...
  SYN1004    
AG13958, >95%
 



IDENTITY
CAS Number:319460-94-1
MDL Number:MFCD17017756
MF:C26H22FN7O
MW:467.5
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>95%
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:15mM in DMSO
Application(s):VEGF

REVIEW
 AG13958 is a VEGF inhibitor that was clinical development by Pfizer in 2006-07 for treatment of age-related macular degeneration (AMD). The drug displays low water solubility and so far in trials delivery has been difficult needing direct injection to be truly effective and it varied by the species used because of species specific differences in eye circulation and vascularization. As a VEGF inhibitor AG13958 was targeted to FLT/TYK receptor inhibition.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of April 20, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.